Community Acquired Pneumonia, Staphylococcal Skin Infections
Conditions
Keywords
Friulimicin B, Lipopeptide Antibiotic, First in Man
Brief summary
The purpose of this study is to study the safety of single doses and multiple doses of Friulimicin B in healthy volunteers. The level of Friulimicin B will be measured in the subjects blood and urine. One part of the study will assess if Friulimicin B in the plasma of subjects has activity against bacteria.
Detailed description
Continued widespread use of antibiotics has promoted the spread of antibiotic resistance and has created an urgent need for antibacterial agents with no known cross resistance to other antibiotics available for humans. Friulimicin B has been shown to be highly active against a range of bacteria including such important pathogens such as methicillin resistant Staphylococcus aureus (MRSA), drug resistant Streptococcus pneumoniae and Glycopeptide resistant Enterococcus spp. These organisms are the causative agents in serious infections such as skin and soft tissue infections, pneumonia, bacteremia and endocarditis, complicated urinary tract infections, and osteomyelitis. This study is the first use of Friulimicin B in man and will examine its safety and a preliminary study will assess if Friulimicin B in the plasma of subjects has activity against bacteria.
Interventions
DRUGFriulimicin B
Intravenous, once daily, single dose
Sponsors
MerLion Pharmaceuticals GmbH
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Male or female healthy subjects * 18-55 years of age * In good health
Exclusion criteria
* Abnormal physical findings of clinical significance at the Screening examination or baseline which would interfere with the objectives of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of single and multiple intravenous doses of Friulimicin B by assessing adverse events, physical examinations,clinical chemistry examination, hematology, ECG and urinalysis. | 5 days |
Secondary
| Measure | Time frame |
|---|---|
| To determine the pharmacokinetic profile of single and multiple intravenous doses of Friulimicin B in healthy subjects | 5 days |
| To determine the bactericidal activity of serum obtained from healthy subjects after administration of Friulimicin B | 5 days |
Countries
Switzerland
Outcome results
None listed